Related Experiment Video
Updated: Sep 19, 2025
Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
Efficacy of Botulinum Toxin Type A for Acute Acquired Comitant Esotropia: An Age-Stratified 2-Year Follow-Up Study
Xiaoning Yu1, Weiyi Pan2, Xiajing Tang1
1Zhejiang University (X.Y., W.P., X.T., Y.Z., L.L., Y.Y., and Z.S.), Eye Center of Second Affiliated Hospital, School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory of Ophthalmology (X.Y., W.P., X.T., Y.Z., L.L., Y.Y., and Z.S.), Hangzhou, China; Zhejiang Provincial Clinical Research Center for Eye Diseases (X.Y., W.P., X.T., Y.Z., L.L., Y.Y., and Z.S.), Hangzhou, China; Zhejiang Provincial Engineering Institute on Eye Diseases (X.Y., W.P., X.T., Y.Z., L.L., Y.Y., and Z.S.), Hangzhou, China.
Purpose:
To assess and compare the 2-year follow-up efficacy of botulinum toxin type A (BTXA) in the treatment of acute acquired comitant esotropia (AACE) across five age groups.
Design:
Retrospective clinical cohort study.
Methods:
A total of 276 patients with AACE who received BTXA injections were enrolled from a single institution between January 2019 and January 2023 (Notably, surgery was recommended for patients >12 years with large-angle esotropia (>50 prism diopters) to reduce failure or recurrence risk). Patients were stratified into five age groups based on intervention age: ≤6 years, >6 to ≤12 years, >12 to ≤20 years, >20 to ≤30 years, and >30 years. The primary outcomes included the cumulative motor and sensory success rates across different age groups, as well as the hazard ratio (HR) for the risk of AACE relapse.
Results:
The median age of the 276 participants was 18 years (interquartile range: 9-30 years), with 125 (45.29%) being female. The overall 2-year motor success rate of BTXA for AACE treatment was 69.03% (95% confidence interval [CI]: 62.30%-74.81%). Notably, the motor success rate exhibited a tendency to decline with age, and patients older than 30 years showed significantly lower motor success rate compared to other age groups (≤6 years: 86.53%, >6-≤12 years: 79.96%, >12-≤20 years: 74.08%, >20-≤30 years: 67.45%, >30 years: 44.29%, Bonferroni-corrected posthoc test: P < .05/4). Similarly, patients aged >30 years demonstrated significantly lower rates of stereopsis recovery post-treatment compared to younger cohorts (Bonferroni-corrected posthoc test: P < .05/4). Furthermore, hours of near-work per day (HR: 1.09, 95% CI: 1.01-1.17) and age (HR: 1.04, 95% CI: 1.02-1.06) were identified as significant risk factors for AACE relapse following BTXA injection.
Conclusions:
In this retrospective cohort study, our findings demonstrated that younger AACE patients (≤30 years) exhibited significantly greater treatment stability and success rates following BTXA injection therapy. Postoperative preservation or achievement of normal stereopsis can serve as a reliable predictor of reduced recurrence risk.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment